Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2

Mostrar otras versiones (2)

Direct-acting antivirals are needed to combat coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). The papain-like protease (PLpro) domain of Nsp3 from SARS-CoV-2 is essential for viral replication. In addition, PLpro dysregulates the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanders, Brian, Pokhrel, Suman, Labbe, Audrey, Mathews, Irimpan, Cooper, Connor, Davidson, Russell, Phillips, Gwyndalyn, Weiss, Kevin, Zhang, Qiu, O'Neill, Hugh, Kaur, Manat, Ferrins, Lori, Schmidt, Jurgen, Reichard, Walter, Surendranathan, Surekha, Parvathareddy, Jyothi, Phillips, Lexi, Rainville, Christopher, Sterner, David, Kumaran, Desigan, Andi, Babak, Babnigg, Gyorgy, Moriarty, Nigel, Adams, Paul, Joachimiak, Andrzej, Hurst, Brett, Kumar, Suresh, Butt, Tauseef, Jonsson, Colleen, Wakatsuki, Soichi, Galanie, Stephanie, Head, Martha, Parks, Jerry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327629/
https://www.ncbi.nlm.nih.gov/pubmed/35898342
http://dx.doi.org/10.21203/rs.3.rs-1840200/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327629/
https://www.ncbi.nlm.nih.gov/pubmed/35898342
http://dx.doi.org/10.21203/rs.3.rs-1840200/v1

Ejemplares similares